Zhejiang Jingxin Pharmaceutical Co Ltd (002020) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zhejiang Jingxin Pharmaceutical Co Ltd (002020) has a cash flow conversion efficiency ratio of 0.040x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥227.64 Million ≈ $33.31 Million USD) by net assets (CN¥5.69 Billion ≈ $831.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review 002020 FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
Zhejiang Jingxin Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Zhejiang Jingxin Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Zhejiang Jingxin Pharmaceutical Co Ltd (002020) total market value for the company's overall valuation and market capitalisation.
Zhejiang Jingxin Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhejiang Jingxin Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anhui Kouzi Distillery Co Ltd
SHG:603589
|
-0.001x |
|
Karooooo Ltd
NASDAQ:KARO
|
0.150x |
|
Hyundai Elevator
KO:017800
|
0.082x |
|
Siloam International Hospitals
JK:SILO
|
0.042x |
|
Browave
TWO:3163
|
0.043x |
|
OVH Groupe SAS
PA:OVH
|
10.219x |
|
Australian United Investment Company Ltd
AU:AUI
|
0.021x |
|
Zymeworks Inc. Common Stock
NASDAQ:ZYME
|
-0.098x |
Annual Cash Flow Conversion Efficiency for Zhejiang Jingxin Pharmaceutical Co Ltd (2002–2025)
The table below shows the annual cash flow conversion efficiency of Zhejiang Jingxin Pharmaceutical Co Ltd from 2002 to 2025. View Zhejiang Jingxin Pharmaceutical Co Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥5.87 Billion ≈ $859.00 Million |
CN¥781.35 Million ≈ $114.34 Million |
0.133x | +10.01% |
| 2024-12-31 | CN¥6.00 Billion ≈ $878.21 Million |
CN¥726.16 Million ≈ $106.26 Million |
0.121x | -18.72% |
| 2023-12-31 | CN¥5.54 Billion ≈ $810.70 Million |
CN¥824.69 Million ≈ $120.68 Million |
0.149x | -10.04% |
| 2022-12-31 | CN¥5.17 Billion ≈ $756.82 Million |
CN¥855.78 Million ≈ $125.23 Million |
0.165x | +119.29% |
| 2021-12-31 | CN¥4.84 Billion ≈ $707.90 Million |
CN¥365.02 Million ≈ $53.41 Million |
0.075x | -42.18% |
| 2020-12-31 | CN¥3.93 Billion ≈ $575.47 Million |
CN¥513.21 Million ≈ $75.10 Million |
0.130x | -9.54% |
| 2019-12-31 | CN¥3.71 Billion ≈ $542.99 Million |
CN¥535.30 Million ≈ $78.33 Million |
0.144x | -1.51% |
| 2018-12-31 | CN¥3.57 Billion ≈ $522.90 Million |
CN¥523.40 Million ≈ $76.59 Million |
0.146x | +50.87% |
| 2017-12-31 | CN¥3.97 Billion ≈ $580.29 Million |
CN¥385.01 Million ≈ $56.34 Million |
0.097x | -6.78% |
| 2016-12-31 | CN¥2.43 Billion ≈ $355.06 Million |
CN¥252.69 Million ≈ $36.98 Million |
0.104x | +62.70% |
| 2015-12-31 | CN¥2.26 Billion ≈ $330.78 Million |
CN¥144.69 Million ≈ $21.17 Million |
0.064x | -57.47% |
| 2014-12-31 | CN¥1.40 Billion ≈ $204.65 Million |
CN¥210.49 Million ≈ $30.80 Million |
0.151x | +10.88% |
| 2013-12-31 | CN¥817.98 Million ≈ $119.70 Million |
CN¥111.03 Million ≈ $16.25 Million |
0.136x | +73.98% |
| 2012-12-31 | CN¥772.58 Million ≈ $113.05 Million |
CN¥60.28 Million ≈ $8.82 Million |
0.078x | -13.88% |
| 2011-12-31 | CN¥766.17 Million ≈ $112.11 Million |
CN¥69.41 Million ≈ $10.16 Million |
0.091x | -51.30% |
| 2010-12-31 | CN¥320.13 Million ≈ $46.84 Million |
CN¥59.55 Million ≈ $8.71 Million |
0.186x | -57.79% |
| 2009-12-31 | CN¥307.17 Million ≈ $44.95 Million |
CN¥135.38 Million ≈ $19.81 Million |
0.441x | +345.67% |
| 2008-12-31 | CN¥303.19 Million ≈ $44.37 Million |
CN¥29.98 Million ≈ $4.39 Million |
0.099x | +133.82% |
| 2007-12-31 | CN¥299.61 Million ≈ $43.84 Million |
CN¥-87.60 Million ≈ $-12.82 Million |
-0.292x | -5856.81% |
| 2006-12-31 | CN¥294.62 Million ≈ $43.11 Million |
CN¥-1.45 Million ≈ $-211.60K |
-0.005x | -102.30% |
| 2005-12-31 | CN¥289.64 Million ≈ $42.38 Million |
CN¥61.82 Million ≈ $9.05 Million |
0.213x | +842.74% |
| 2004-12-31 | CN¥284.03 Million ≈ $41.56 Million |
CN¥6.43 Million ≈ $940.95K |
0.023x | -95.66% |
| 2003-12-31 | CN¥88.44 Million ≈ $12.94 Million |
CN¥46.18 Million ≈ $6.76 Million |
0.522x | -27.68% |
| 2002-12-31 | CN¥63.02 Million ≈ $9.22 Million |
CN¥45.50 Million ≈ $6.66 Million |
0.722x | -- |
About Zhejiang Jingxin Pharmaceutical Co Ltd
Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China and internationally. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemi… Read more